BEST UNLIMITED TURBO LONG CERTIFICATE - MODERNA | Market Closed - Euronext Paris 07:18:57 20/06/2024 BST | ||
| 4.545 EUR | +2.25% |
|
| Current month | -18.89% | ||
| 1 month | -4.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 4.545 | +2.25% |
| 19/06/24 | 4.445 | -5.93% |
| 18/06/24 | 4.725 | -8.25% |
| 17/06/24 | 5.15 | -1.15% |
| 14/06/24 | 5.21 | -10.17% |
Real-time Euronext Paris
Last update June 20, 2024 at 07:18 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| L899S | |
| ISIN | DE000SU545Q5 |
| Date issued | 21/12/2023 |
| Strike | 85.68 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.03 € |
|---|---|
| Lowest since issue | 0.335 € |
| Spread | 0.1 € |
| Spread % | 2.17% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- L899S Certificat
